Beruflich Dokumente
Kultur Dokumente
BIOPHARMACEUTICALS
Cardiovascular Devices
Prosthetic Heart Valve
Peripheral Vascular Devices
Cardiovascular Monitoring & Diagnostic Devices
Cardiovascular Surgery
Cardiac Rhythm Management
Cardiovascular Prosthetic Devices
Interventional Cardiology
Cardiac Assist Devices
Wound Care Management
Hospital Supplies
Syringes and Needles
Disposable Hospital & Surgical Supplies
Drug Delivery Devices
Inhalation Systems
Needle Free Injections
Infusion Systems
Diabetes Care Devices
Insulin Delivery & Glucose Monitoring
Ophthalmic Devices
Cataract Surgery Devices
Ophthalmic Diagnostic Equipment
Refractive Surgery Devices
ENT Devices
Hearing Implants
Diagnostic Devices
Electrosurgical Devices
Dental Equipment & Accessories
Diagnostic Imaging & MRI Systems
C/T Systems & Mammography Equipment
X-Ray & Ultrasound Systems
Nuclear Imaging Equipment
Contrast Media Injectors
Bone Densitometry
Anesthesia and Respiratory Devices
Anesthesia Machines & Disposables
Respiratory Devices & Disposables
Sleep Apnea Diagnostic Systems
Healthcare IT
Medical Imaging Information Systems
Nephrology and Urology Devices
Renal Dialysis Equipment
Orthopedic Devices
Orthobiologics & Arthroscopy
Joint Reconstruction
Trauma Fixation
Orthopedic Prosthetics
Cranium Maxillofacial Fixation (CMF)
Spinal Surgery
Endoscopy Devices & instruments
Rigid & Flexible Endoscope
In Vitro Diagnostics
Genetic Testing
Clinical Chemistry
Hematology
Immuno Chemistry
Infectious Immunology
Histology And Cytology
Patient Monitoring
Multiparameter Patient Monitoring
Micro-Electromechanical Systems
Non-invasive Blood Pressure Monitors
Neurology Devices
Neurostimulation Devices
Interventional Neurology
CSF Management
Neurosurgical Products
Radiosurgery
Diabetic Nephropathy
Diabetic Retinopathy
Hypercholesterolemia
Oral Mucositis
Gout
Acute Lymphocytic Leukemia
Bone Metastasis
Brain Cancer
Breast Cancer
Cervical Cancer
Chronic Lymphocytic Leukemia
Endometrial Cancer
Ewing Sarcoma
Gastric Cancer
Gastrointestinal Stromal Tumors
Head And Neck Cancer
Hodgkin Lymphoma
Kidney Cancer
Liver Cancer
Malignant Mesothelioma
Medullary Thyroid Cancer
Melanoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Testicular Cancer
Thyroid Cancer
Age Related Macular Degeneration
Keratoconjunctivitis sicca (Dry Eye)
Retinal Vein Occlusion
Acute Respiratory Distress
Syndrome
Sepsis
Staphylococcal Infections
Acute Coronary Syndrome
Angina Pectoris
Atrial Fibrillation
Coronary Artery Disease (CAD)
Critical Limb Ischemia
Hypertension
Pulmonary Arterial Hypertension
Acute Pain
Anxiety Disorders
Chronic Pain
Dementia
Diabetic Neuropathy
Obsessive-Compulsive Disorder
Osteoarthritis Pain
Parkinson's Disease
Post-Traumatic Stress Disorder
Restless Legs Syndrome
Schizophrenia
Traumatic Brain Injury
Liver Cirrhosis
Childhood Enuresis
Growth Hormone Disorders
Hyperparathyroidism
Hyperthyroidism
Guillain-Barre Syndrome
Cytomegalovirus
Fungal Infections
Gram-Negative Bacterial Infections
H1N1 Infection
Herpes Zoster
HIV-1 Infection
Human Papillomavirus Infections
Staphylococcus Aureus (MRSA)
Venture Capital
LEAD INVESTORS
DIRECT INVESTORS
Mature
T R A N S F O R M I N G H E A LTH C A R E C A P ITAL M A R K E T S
on behalf of
Growth
Launch
N
D
A
Approv
al
Phase
III
Phase II
Phase I
Develop
ment
Angels / Founders
I
N
D
EXIT
SEED
Discover
y
Superior Outcomes
12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
Seed-to-Exit
Direct
Investment
NO Fee
NO Carry
1. Reduce Risk
Messaging
&
Notifications
Prediction &
Sentiment Data
Less
Correlation
Proprietary
Events
Rules-Based
Deal Flow
Ratings &
Reviews
6,000 +
Growth
Companies
2. Enhance Returns
3. Expand Access to Capital
NO
Adverse
Selection
Zero
Un-Invested
Capital
Reporting &
Communications
Real-Time
Valuations &
Research
Shorter Exit
Horizons
Superior Outcomes
12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
NO Fee
NO Carry
6,000 +
Growth
Companies
Seed-to-Exit
Direct
Investment
Less
Correlation
Rules-Based
Deal Flow
Proprietary
Events
Ratings &
Reviews
Reducing Risk
Zero
Un-Invested
Capital
Messaging
&
Notifications
Reporting &
Communications
Prediction &
Sentiment Data
Real-Time
Valuations &
Research
NO
Adverse
Selection
Shorter Exit
Horizons
Superior Outcomes
12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
NO Fee
NO Carry
6,000 +
Growth
Companies
Seed-to-Exit
Direct
Investment
Less
Correlation
Rules-Based
Deal Flow
Proprietary
Events
Ratings &
Reviews
Enhance Returns
Zero
Un-Invested
Capital
Messaging
&
Notifications
Reporting &
Communications
Prediction &
Sentiment Data
Real-Time
Valuations &
Research
NO
Adverse
Selection
Shorter Exit
Horizons
Superior Outcomes
12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
NO Fee
NO Carry
6,000 +
Growth
Companies
Seed-to-Exit
Direct
Investment
Less
Correlation
Rules-Based
Deal Flow
Proprietary
Events
Ratings &
Reviews
Zero
Un-Invested
Capital
Messaging
&
Notifications
Reporting &
Communications
Prediction &
Sentiment Data
Real-Time
Valuations &
Research
NO
Adverse
Selection
Shorter Exit
Horizons
Superior Outcomes
12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
Seed-to-Exit
Direct
Investment
Rules-Based
Deal Flow
Ratings &
Reviews
Messaging
&
Notifications
Prediction &
Sentiment Data
NO Fee
NO Carry
1. Reduce Risk
2. Heighten Returns
3. Expand Access to Capital
NO
Adverse
Selection
6,000 +
Growth
Companies
Less
Correlation
Proprietary
Events
Zero
Un-Invested
Capital
Reporting &
Communications
Real-Time
Valuations &
Research
Shorter Exit
Horizons